RxDoctor Payments Data

Cheryl Johnson, MD

Family Medicine · Lehi, UTNPI 1417066671

Payments from drug & device makers

$9,169in general payments, 2019–2025

Across 545 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Astellas Pharma US Inc$1K
  • AstraZeneca$675
  • Novartis$549
  • Lilly USA, LLC$447
  • Pfizer$426
  • plus $4K from 54 others

What the payments were for

  • Travel & lodging$5166%
  • Food & beverage$8,15489%
  • Education$5005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,562
Astellas Pharma US Inc36$1,020
AstraZeneca45$675
Novartis3$549
Lilly USA, LLC29$447
Pfizer54$426
Antares Pharma, Inc.19$411
Boehringer Ingelheim15$295
Ironshore Pharmaceuticals Inc.14$257
Sanofi-aventis U.S. LLC17$230
Amgen14$225
GSK15$205
Tris Pharma Inc11$194
Johnson & Johnson8$159
Amarin Pharma, Inc.8$130
Sunovion Pharmaceuticals Inc.9$117
Novo Nordisk7$103
Boston Scientific6$99
Xeris Pharmaceuticals, Inc.5$99
Corium, LLC5$90
Takeda Pharmaceuticals U.S.A., Inc.9$90
Axsome Therapeutics, Inc.4$89
Abbott4$87
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$81
Kowa Pharmaceuticals America, Inc.6$80
Merck5$76
Corcept Therapeutics4$74
Idorsia Pharmaceuticals US Inc4$68
Phathom Pharmaceuticals, Inc.5$68
Bayer4$67
Mylan Specialty L.p.3$59
Edwards Lifesciences3$57
Neuronetics, Inc.1$56
Nestle Healthcare Nutrition Inc.3$55
Supernus Pharmaceuticals, Inc.3$51
Dynavax Technologies Corporation3$48
Teva Pharmaceuticals USA, Inc.3$44
Avanir Pharmaceuticals, Inc.3$43
Sumitomo Pharma America, Inc.4$38
Biohaven Pharmaceutical Holding Company Ltd.2$38
Strongbridge US Inc.2$37
Vanda Pharmaceuticals Inc.1$35
Aimmune Therapeutics, Inc.2$33
Medtronic(2 entities)2$32
Jazz Pharmaceuticals Inc.2$31
Cranial Technologies, Inc2$30
Biohaven Pharmaceuticals, Inc.2$29
Mayne Pharma Commercial LLC1$26
Dexcom, Inc.2$25
Daiichi Sankyo Inc.1$24
Ascendis Pharma Endocrinology Inc1$22
Viatris Specialty LLC1$22
Otsuka America Pharmaceutical, Inc.1$19
Organon2$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Alnylam Pharmaceuticals Inc.1$18
Upsher-smith Laboratories LLC1$16
Almatica Pharma LLC1$15
Ultragenyx Pharmaceutical Inc.1$15
BD1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,169 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$117,737
Medicare patients
288
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$109,203
TrulicityDulaglutide79$90,185
FarxigaDapagliflozin Propanediol70$64,114
JardianceEmpagliflozin62$60,101
XareltoRivaroxaban39$48,629
JanuviaSitagliptin Phosphate24$34,747
MounjaroTirzepatide28$32,563
OzempicSemaglutide21$25,908
Soliqua 100-33Insulin Glargine/Lixisenatide27$25,865
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$23,164
MyrbetriqMirabegron17$15,782
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$14,946
Levothyroxine Sodium674$7,956
SymbicortBudesonide/Formoterol Fumarate18$6,573
SynthroidLevothyroxine Sodium104$6,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$447$122,749107 claims
PfizerEliquis, Premarin$426$115,304145 claims
AstraZenecaFarxiga, Symbicort$675$70,68788 claims
Boehringer IngelheimJardiance, Spiriva Respimat$295$65,80673 claims
Johnson & JohnsonXarelto$159$48,62939 claims
MerckJanuvia$76$34,74724 claims
Novo NordiskOzempic$103$25,90821 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$230$25,86527 claims
Astellas Pharma US IncMyrbetriq$1,020$15,78217 claims
GSKBreo Ellipta, Incruse Ellipta$205$9,23922 claims
AbbVieSynthroid$1,562$6,278104 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$90$5,74015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.

Other family medicine in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →